Search Results - "Bleehen, N. M."

Refine Results
  1. 1

    Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma by Bleehen, N M, Newlands, E S, Lee, S M, Thatcher, N, Selby, P, Calvert, A H, Rustin, G J, Brampton, M, Stevens, M F

    Published in Journal of clinical oncology (01-04-1995)
    “…Sixty patients with metastatic melanoma were treated in a phase II study with the imidazotetrazine derivative temozolamide to assess further the efficacy…”
    Get more information
    Journal Article
  2. 2

    Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma by BOWER, M, NEWLANDS, E. S, BLEEHEN, N. M, BRADA, M, BEGENT, R. J. H, CALVERT, H, COLQUHOUN, I, LEWIS, P, BRAMPTON, M. H

    “…Patients with progressive or recurrent supratentorial high-grade gliomas were entered into a multicentre phase II trial to evaluate the efficacy and toxicity…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer by Boote, D J, Dennis, I F, Twentyman, P R, Osborne, R J, Laburte, C, Hensel, S, Smyth, J F, Brampton, M H, Bleehen, N M

    Published in Journal of clinical oncology (01-02-1996)
    “…To determine the maximum-tolerated dose (MTD) and toxicity of PSC 833 infusion administered with etoposide for 5 days in patients with cancer, and to determine…”
    Get more information
    Journal Article
  5. 5

    Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance by REEVE, J. G, XIONG, J, MORGAN, J, BLEEHEN, N. M

    Published in British journal of cancer (01-05-1996)
    “…As a first step towards elucidating the potential role(s) of bcl-2 and bcl-2-related genes in lung tumorigenesis and therapeutic responsiveness, the expression…”
    Get full text
    Journal Article
  6. 6

    p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus by Sundaresan, V, Ganly, P, Hasleton, P, Rudd, R, Sinha, G, Bleehen, N M, Rabbitts, P

    Published in Oncogene (01-10-1992)
    “…Bronchial epithelial dysplasia is believed to precede invasive squamous cell carcinoma of the lung. Six paired dysplasia and tumour samples were distinguished…”
    Get more information
    Journal Article
  7. 7

    A phase I study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma by Ford, J, Osborn, C, Barton, T, Bleehen, N.M

    Published in European journal of cancer (1990) (01-10-1998)
    “…RMP-7, a nine amino acid peptide bradykinin agonist, increases the delivery of hydrophilic compounds across the blood–tumour barrier. In this dose ranging…”
    Get full text
    Journal Article
  8. 8

    Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II by TWELVES, C. J, GARDNER, C, RODRIGUEZ, A, JUDSON, I, BLEEHEN, N. M, FLAVIN, A, SLUDDEN, J, DENNIS, I, DE BONO, J, BEALE, P, VASEY, P, HUTCHISON, C, MACHAM, M. A

    Published in British Journal of Cancer (01-08-1999)
    “…DACA, also known as XR5000, is an acridine derivative active against both topoisomerase I and II. In this phase I study, DACA was given as a 3-h intravenous…”
    Get full text
    Journal Article
  9. 9

    The influence of carbogen breathing on tumour tissue oxygenation in man evaluated by computerised p02 histography by Falk, S J, Ward, R, Bleehen, N M

    Published in British journal of cancer (01-11-1992)
    “…Tumour tissue oxygenation has been measured in man during carbogen breathing (95% O2, 5% CO2) using a commercially available polarographic electrode system…”
    Get full text
    Journal Article
  10. 10

    Perfusion changes in the RIF-1 tumour and normal tissues after carbogen and nicotinamide, individually and combined by HONESS, D. J, BLEEHEN, N. M

    Published in British journal of cancer (01-06-1995)
    “…The strategy of combining carbogen breathing and nicotinamide to overcome chronic and acute hypoxia respectively is being evaluated clinically. The effects of…”
    Get full text
    Journal Article
  11. 11

    Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumours by SUNDARESAN, V, REEVE, J. G, STENNING, S, STEWART, S, BLEEHEN, N. M

    Published in British journal of cancer (01-08-1991)
    “…The present study examines the relationship between neuroendocrine (NE) differentiation and the clinical behaviour of non-small cell lung cancer (NSCLC)…”
    Get full text
    Journal Article
  12. 12

    Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors by REEVE, J. G, MORGAN, J, SCHWANDER, J, BLEEHEN, N. M

    Published in Cancer research (Chicago, Ill.) (01-10-1993)
    “…The insulin-like growth factors (IGFs) have been implicated in the autocrine and/or paracrine growth of a number of tumor types, including lung tumors…”
    Get full text
    Journal Article
  13. 13

    Carbogen breathing with nicotinamide improves the oxygen status of tumours in patients by LAURENCE, V. M, WARD, R, DENNIS, I. F, BLEEHEN, N. M

    Published in British journal of cancer (01-07-1995)
    “…Nicotinamide and carbogen breathing are both effective radiosensitisers in experimental tumour models and are even more effective in combination. This study…”
    Get full text
    Journal Article
  14. 14

    Measurements of resting energy expenditure and body composition before and after treatment of small cell lung cancer by Jebb, S A, Osborne, R J, Dixon, A K, Bleehen, N M, Elia, M

    Published in Annals of oncology (01-12-1994)
    “…Many patients with small cell lung cancer are reported to lose weight, but the mechanism of this effect is unclear. Measurements of resting energy expenditure…”
    Get more information
    Journal Article
  15. 15

    Simultaneous evaluation of the effects of RF hyperthermia on the intra- and extracellular tumor pH by Jayasundar, Rama, Honess, Davina, Hall, Laurance D., Bleehen, Norman M.

    Published in Magnetic resonance in medicine (01-01-2000)
    “…31P‐magnetic resonance spectroscopy (MRS) and a fiberoptic pH meter were used simultaneously to follow the changes in intra‐ (pHi) and extracellular pH (pHe),…”
    Get full text
    Journal Article
  16. 16

    Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells by Smith, P J, Souès, S, Gottlieb, T, Falk, S J, Watson, J V, Osborne, R J, Bleehen, N M

    Published in British journal of cancer (01-11-1994)
    “…As an approach to the rational design of combination chemotherapy involving the anti-cancer DNA topoisomerase II poison etoposide (VP-16), we have studied the…”
    Get full text
    Journal Article
  17. 17

    Expression of insulinlike growth factor (IGF) and IGF-binding protein genes in human lung tumor cell lines by Reeve, J G, Brinkman, A, Hughes, S, Mitchell, J, Schwander, J, Bleehen, N M

    “…The presence of multiple, low-molecular-weight, insulinlike growth factor (IGF)-binding proteins in lung tumor cell-conditioned medium and lung cancer patient…”
    Get more information
    Journal Article
  18. 18

    Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma by KERR, D. J, MAUGHAN, T, NEWLANDS, E, RUSTIN, G, BLEEHEN, N. M, LEWIS, C, KAYE, S. B

    Published in British journal of cancer (01-07-1989)
    “…Flavone acetic acid (FAA), 8.6 gm-2 has been administered by 6h intravenous infusion to 19 patients with advanced colorectal carcinoma and 15 patients with…”
    Get full text
    Journal Article
  19. 19

    Production of immunoreactive insulin-like growth factor-I (IGF-I) and IGF-I binding proteins by human lung tumours by REEVE, J. G, PAYNE, J. A, BLEEHEN, N. M

    Published in British journal of cancer (01-05-1990)
    “…The production of insulin-like growth factor I (IGF-I) and IGF-I binding proteins (BPs) by human lung tumour cell lines in vitro has been examined and the…”
    Get full text
    Journal Article
  20. 20

    A short fractionation radiotherapy treatment for poor prognosis patients with high grade glioma by Ford, J.M., Stenning, S.P., Boote, D.J., Counsell, R., Falk, S.J., Flavin, A., Laurence, V.M., Bleehen, N.M.

    “…Thirty-two patients prospectively identified as having poor prognosis high grade glioma, with a MRC prognostic score >25, were treated with a short palliative…”
    Get full text
    Journal Article Conference Proceeding